CompletedPhase 2NCT01681121

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Studying Narcolepsy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Jazz Pharmaceuticals
Principal Investigator: David Ward, MD
Aerial BioPharma, LLC
Intervention: ADX-N05(drug)
Enrollment: 93 target
Eligibility: 18-70 years · All sexes
Timeline: 2012 – 2013

Study locations (28)

Sleep Disorders Center of Alabama, Birmingham, Alabama, United States
Pulmonary Associates, Phoenix, Arizona, United States
Stanford Sleep Medicine Center, Redwood City, California, United States
Pacific Research Network, San Diego, California, United States
Sleep-Alertness Disorders Center, Aurora, Colorado, United States
PAB Clinical Research, Brandon, Florida, United States
Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States
NeuroTrials Research, Inc., Atlanta, Georgia, United States
Sleep Disorders Center of Georgia, Atlanta, Georgia, United States
SleepMed of Central Georgia, Macon, Georgia, United States
Chicago Research Center, Chicago, Illinois, United States
Community Research, Crestview Hills, Kentucky, United States
Kentucky Research Group, Louisville, Kentucky, United States
The Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States
Pulmonary and Critical Care Associates of Baltimore, Towson, Maryland, United States
+13 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01681121 on ClinicalTrials.gov

Other trials for Narcolepsy

Additional recruiting or active studies for the same condition.

See all trials for Narcolepsy →

← Back to all trials